A Phase 2 interventional study of Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy and Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy in Type 2 Diabetes Mellitus, sponsored by Indonesia University. Not yet recruiting at 1 site in Indonesia. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Indonesia University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Diabetes Mellitus, Type 2 by Indonesia University — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Indonesia University.
Among the 13 studies in Diabetes Mellitus, Type 2 by Indonesia University, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 2, and was the 13th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 13 studies in Diabetes Mellitus, Type 2 by Indonesia University are open now, in 1 country. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 35–59
Indonesia University · Sites in Indonesia
Ages 8–40 · Healthy volunteers
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 4 2
First in 2016; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 55 across the 12 interventional studies, 1,000 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Indonesia University is the lead sponsor of 444 studies on the registry; 54 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Diabetes Mellitus, Type 2 by Indonesia University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label randomized controlled trial with a pre-and-post-test control group design to evaluate the effect of Mesenchymal Stromal/Stem Cells-Derived Exosomes (MSC-Exos) as an adjunctive therapy on glycemic control and clinical outcomes in patients with Type 2 Diabetes Mellitus (T2DM). The study aims to determine if the addition of exosome therapy to standard care can improve glycemic parameters (fasting blood glucose, 2-hour postprandial glucose, HbA1c, and C-peptide), quality of life, and inflammatory biomarkers (IL-6, IL-10, D-dimer, and CRP). The study will involve 50 subjects, randomly allocated into two groups: an intervention group and a control group. The intervention group will receive standard T2DM therapy plus a combination of exosomes (1 vial Exo-HWS + 1 vial Exo-HUVEC). The control group will receive standard T2DM therapy plus 1 vial Exo-HWS. The study duration is from June to December 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receives standard therapy for Diabetes Mellitus (DM) plus a combination of exosomes (1 vial Exo-HWS + 1 vial Exo-HUVEC). Administered as a monthly intravenous bolus injection for three months
Biological: Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy
Receives standard therapy for DM plus 1 vial of Exo-HWS. Administered as a monthly intravenous bolus injection for three months.
Biological: Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy
The intervention group will receive standard DM therapy plus an exosome combination of 1 vial Exo-HWS + 1 vial Exo-HUVEC, administered monthly for three months via intravenous bolus injection.
The control group will receive standard DM therapy plus 1 vial Exo-HWS, administered monthly for three months via intravenous bolus injection.
Fasting Blood Glucose (FBG)
Change in FBG levels from baseline to the end of the third month. Unit of Measurement: mg/dL
Time frame: Baseline (Day 0) and End of the 3rd Month
2-Hour Postprandial Glucose
Change in 2-hour postprandial glucose levels from baseline to the end of the third month. Unit of Measurement: mg/dL
Time frame: Baseline (Day 0) and End of the 3rd Month
HbA1c
Change in HbA1c levels from baseline to the end of the third month. Unit of Measurement: %
Time frame: Baseline (Day 0) and End of the 3rd Month
C-peptide
Change in C-peptide levels from baseline to the end of the third month. Unit of Measurement: ng/m
Time frame: Baseline (Day 0) and End of the 3rd Month
Quality of Life using DQoL
Change in quality of life scores as measured by the Diabetes Quality of Life (DQoL) questionnaire from baseline to the end of the third month. Unit of Measurement: Score
Time frame: Baseline (Day 0) and End of the 3rd Month
IL-6
Change in Interleukin-6 (IL-6) levels from baseline to the end of the third month. Unit of Measurement: mg/L
Time frame: Baseline (Day 0) and End of the 3rd Month
IL-10
Change in Interleukin-10 (IL-10) levels from baseline to the end of the third month. Unit of Measurement: mg/L
Time frame: Baseline (Day 0) and End of the 3rd Month
D-dimer
Change in D-dimer levels from baseline to the end of the third month. Unit of Measurement: ng/mL
Time frame: Baseline (Day 0) and End of the 3rd Month
CRP
Change in C-Reactive Protein (CRP) levels from baseline to the end of the third month. Unit of Measurement: mg/L
Time frame: Baseline (Day 0) and End of the 3rd Month
Plan to share: No — There is no explicit plan to share Individual Participant Data (IPD) from this study. The research team's commitment to participant confidentiality is paramount. The informed consent form assures participants that their data and information will be kept confidential and will be used solely for the purpose of the research, education, and scientific development, without disclosing their identity. This approach aligns with the ethical clearance obtained for the study, which emphasizes protecting participant identity.
Start is estimated for Sep 2025; primary completion for Dec 2025, 3 months later.
Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 3 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.